We aimed to validate the Czech version of the MATRICS Consensus Cognitive Battery (MCCB). The MCCB is a test battery designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. The valid, reliable and replicable measurement of cognition in schizophrenia is of substantial importance for such clinical trial studies. We performed a psychometric analysis of the MCCB composite and domain scores based on ROC analysis of 67 schizophrenia patients and 67 age- and education-matched healthy controls from a total sample of 220 controls. Also, we correlated MCCB variables with scales measuring psychosocial functioning (Personal and Social Performance scale; PSP). The internal consistency of all 10 tests in the MCCB battery was good (Cronbach's α = 0.85 (95% CI [0.83, 0.88])). The discriminative validity for the detection of neurocognitive dysfunction in schizophrenia based on the area under the curve of MCCB composite T-score was ≥90% (95% CI [0.85, 0.96]) and all MCCB domains showed ps < .001. The MCCB global composite and the Speed of Processing domain score significantly predicted the PSP ratings. A confirmatory factor analysis on the whole control sample (N = 220) showed an optimal fit for a 6-factor in comparison to 1-factor solution. In conclusion, we found high discriminative validity for the Czech MCCB version, similar to the differentiation of schizophrenia versus healthy control groups in the original MCCB studies. We also established the factorial validity of the MCCB and showed that the overall composite of the MCCB predicts psychosocial functioning in the patient group.

中文翻译：

---

精神分裂症认知缺陷的概况和捷克 MATRICS 共识认知电池的因素结构

我们旨在验证捷克版的 MATRICS 共识认知电池 (MCCB)。MCCB 是一个测试组，旨在评估精神分裂症患者临床试验中的认知治疗效果。有效、可靠和可复制的精神分裂症认知测量对于此类临床试验研究具有重要意义。我们基于对 67 名精神分裂症患者和 67 名年龄和教育相匹配的健康对照的 ROC 分析，对 220 名对照者的总样本进行了 MCCB 综合评分和领域评分的心理测量分析。此外，我们将 MCCB 变量与衡量社会心理功能的量表（个人和社会绩效量表；PSP）相关联。MCCB 电池中所有 10 项测试的内部一致性良好（Cronbach's α = 0.85（95% CI [0.83, 0.88]））。基于 MCCB 复合 T 分数曲线下面积检测精神分裂症神经认知功能障碍的区分效度≥90%（95% CI [0.85, 0.96]），所有 MCCB 域均显示 ps < .001。MCCB 全球综合和处理速度领域得分显着预测了 PSP 评级。对整个对照样本 (N = 220) 的验证性因子分析显示，与 1 因子解决方案相比，6 因子的最佳拟合。总之，我们发现捷克 MCCB 版本的高区分效度，类似于原始 MCCB 研究中精神分裂症与健康对照组的区别。我们还建立了 MCCB 的因子效度，并表明 MCCB 的整体组合预测了患者组的心理社会功能。